Shionogi-ViiV Healthcare announces initial data from pivotal phase III study of dolutegravir in HIV
This drug will compete against raltegravir (Merck) and elvitegravir (Gilead). It will be dosed once a day for treatment naive patients and twice a day for treatment experienced. Issued: Monday 02 April 2012, London, UK Press release issued by Shionogi-ViiV Healthcare LLC, a joint venture between ViiV Healthcare Ltd (a global specialist HIV company established …